Geniposide enhances cisplatin sensitivity in non-small cell lung cancer through PUMA-mediated apoptotic pathway
Cellular Signalling · 2026
DOI: 10.1016/j.cellsig.2026.112486 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cellular Signalling, 2026. Verfasst von Jingjing Sun und 7 weiteren Autor:innen. Beteiligte Einrichtung: Qingdao Key Laboratory of Common Diseases, Qingdao Municipal Hospital, School of Medicine and Pharmacy, Ocean University of China, Qingdao 266071, Ch…. Hauptthemen laut MEDLINE: Cisplatin, Carcinoma, Non-Small-Cell Lung, Iridoids, Apoptosis. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Key Technology Research and Development Program of Shandong, Shandong Province Natural Science Foundation, National Health Commission of the People's Republic of China.
Abstract (Originalsprache)
BACKGROUND: Cisplatin-based chemotherapy remains the standard treatment for advanced non-small cell lung cancer (NSCLC); however, its efficacy is constrained by acquired drug resistance and dose-limiting toxicity. Dysregulated apoptosis is recognized as a key mechanism contributing to cisplatin resistance in NSCLC. Geniposide, an active component of traditional Chinese medicine, has demonstrated broad-spectrum antitumor activity; however, its role in cisplatin resistance remains unclear. METHODS: Network pharmacology was employed to identify potential targets. The platinum-resistant A549/DDP cell line and its parental A549 line were used as in vitro models. Functional assays were performed to evaluate proliferation, apoptosis, migration, and mitochondrial membrane potential. RNA sequencing and gene knockdown/overexpression approaches were performed to investigate the underlying molecular mechanisms. An A549/DDP xenograft model was used to assess in vivo therapeutic efficacy. RESULTS: Network pharmacology analysis identified 125 common targets enriched in apoptosis and p53 signaling pathways. Geniposide significantly enhanced cisplatin sensitivity in A549/DDP cells by inhibiting proliferation and migration while promoting apoptosis and inducing mitochondrial membrane potential dissipation. RNA-seq identified PUMA as a key pro-apoptotic mediator. Combined treatment markedly upregulated PUMA expression, accompanied by activation of p53 signaling. Silencing of PUMA or p53 attenuated the chemosensitizing and pro-apoptotic effects, whereas PUMA overexpression independently reduced cisplatin IC₅₀ values. In vivo, geniposide combined with low-dose cisplatin achieved tumor suppression comparable to high-dose cisplatin without inducing systemic toxicity. CONCLUSION: These findings demonstrate that geniposide enhances cisplatin sensitivity in NSCLC by activating the p53-PUMA-mediated mitochondrial apoptotic pathway, thereby providing a potential strategy for overcoming chemotherapy resistance with improved safety.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Qingdao Key Laboratory of Common Diseases, Qingdao Municipal Hospital, School of Medicine and Pharmacy, Ocean University of China, Qingdao 266071, China; Department of Respiratory and Critical Care Medicine, Qingdao Mun…
- Department of Respiratory and Critical Care Medicine, Qingdao Municipal Hospital, University of Health and Rehabilitation Sciences, Qingdao 266071, China; NHC Key Laboratory of Cardiopulmonary Rehabilitation and Functio…
- NHC Key Laboratory of Cardiopulmonary Rehabilitation and Functional Recovery, University of Health and Rehabilitation Science, Qingdao 266071, China; Clinical Research Center, Qingdao Municipal Hospital, University of H…
- Central Laboratories, Qingdao Municipal Hospital, University of Health and Rehabilitation Science, Qingdao 266071, China. Electronic address: yumengchao2006@163.com.
- NHC Key Laboratory of Cardiopulmonary Rehabilitation and Functional Recovery, University of Health and Rehabilitation Science, Qingdao 266071, China; Central Laboratories, Qingdao Municipal Hospital, University of Healt…
Förderung
- Key Technology Research and Development Program of Shandong
- Shandong Province Natural Science Foundation
- National Health Commission of the People's Republic of China
Zitieren
APA
Sun, J., Han, Y., Wang, C., Wang, T., Hu, W., Yu, M., Wang, Y., & Han, W. (2026). Geniposide enhances cisplatin sensitivity in non-small cell lung cancer through PUMA-mediated apoptotic pathway. Cellular Signalling. https://doi.org/10.1016/j.cellsig.2026.112486
Vancouver
Sun J, Han Y, Wang C, Wang T, Hu W, Yu M, et al. Geniposide enhances cisplatin sensitivity in non-small cell lung cancer through PUMA-mediated apoptotic pathway. Cellular Signalling. 2026. doi:10.1016/j.cellsig.2026.112486
BibTeX
@article{Sun2026,
author = {Sun, Jingjing and Han, Yaozu and Wang, Chen and Wang, Tianying and Hu, Wenmin and Yu, Mengchao and Wang, Yixuan and Han, Wei},
title = {Geniposide enhances cisplatin sensitivity in non-small cell lung cancer through PUMA-mediated apoptotic pathway},
journal = {Cellular Signalling},
year = {2026},
doi = {10.1016/j.cellsig.2026.112486}
}
EUVIMED